Hyperthermia exhibits anti-vascular activity in the sc BT4An rat glioma:: lack of interaction with the angiogenesis inhibitor batimastat

被引:13
作者
Eikesdal, HP [1 ]
Bjorkhaug, ST [1 ]
Dahl, O [1 ]
机构
[1] Univ Bergen, Haukeland Univ Hosp, Dept Oncol, N-5021 Bergen, Norway
关键词
hyperthermia; batimastat; anti-vascular therapy; tumour blood flow;
D O I
10.1080/02656730110090712
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the anti-vascular activity of local hyperthermia (44degreesC, 60 min) in s.c. BT(4)An rat gliomas, and the influence on tumour growth of hyperthermia and the anti-angiogenic compound batimastat (30 mg/kg i.p.). Heat-induced vascular damage was assessed in small (82 mm 3) and large (171 mm 3) tumours using confocal microscopy and immunostaining for von Willebrand factor. The influence of hyperthermia on tumour blood flow was measured using the (RbCl)-Rb-86 method. The anti-tumour activity of hyperthermia (one or two fractions a week apart) and batimastat (7 or 14 daily injections) and various combination schedules were examined. Hyperthermia disrupted 25-50% of the vasculature in the BT(4)An tumours, and the vascular damage was most extensive in the central part of the large tumours. The heated tumours exhibited a 40-60% blood flow reduction, which persisted until the last measurement after 24 h. One fraction of hyperthermia caused a significant growth delay of 4 days, compared with the control group (p = 0.01), but no additional tumour response was produced by a second heating session. Batimastat had no influence on tumour growth and the combination of drug and local heating did not enhance the tumour response, compared with heating alone. It was concluded that hyperthermia at 44degreesC for 60 min exhibits anti-vascular activity and inhibits tumour growth in the BT(4)An tumour model. Batimastat had no effect on tumour growth.
引用
收藏
页码:141 / 152
页数:12
相关论文
共 54 条
[1]  
Altman DG, 1990, PRACTICAL STAT MED R
[2]   TUMOR VASCULATURE - A POTENTIAL THERAPEUTIC TARGET [J].
BAILLIE, CT ;
WINSLET, MC ;
BRADLEY, NJ .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :257-267
[3]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[4]   Matrix metalloproteinase inhibition: A review of anti-tumour activity [J].
Brown, PD ;
Giavazzi, R .
ANNALS OF ONCOLOGY, 1995, 6 (10) :967-974
[5]  
BROWN PD, 1993, CURR OPIN INVEST DR, V2, P617
[6]  
Dark GG, 1997, CANCER RES, V57, P1829
[7]  
DAVIES B, 1993, CANCER RES, V53, P2087
[8]   VASCULAR OCCLUSION AND TUMOR-CELL DEATH [J].
DENEKAMP, J ;
HILL, SA ;
HOBSON, B .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :271-275
[9]   VASCULAR ATTACK AS A THERAPEUTIC STRATEGY FOR CANCER [J].
DENEKAMP, J .
CANCER AND METASTASIS REVIEWS, 1990, 9 (03) :267-282
[10]   Anti-angiogenic agents: clinical trial design and therapies in development [J].
Deplanque, G ;
Harris, AL .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (13) :1713-1724